MedTrace Logo

Dose Ranging Study of RPL554 in Chronic Obstructive Pulmonary Disease (COPD) Patients

NCT03443414 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 405

Last updated 2019-06-04

Study results available
· View outcomes & findings →

Summary

The study investigates the effect of 4 weeks of twice daily treatment of four different doses of RPL554 (a phosphodiesterase \[PDE\]3/4 inhibitor) or placebo in patients with moderate to severe chronic obstructive pulmonary disease (COPD). Patients will be equally allocated to one of the five treatment options.

Conditions

Interventions

DRUG

RPL554 suspension

A dual PDE3/PDE 4 inhibitor

DRUG

Placebo

Placebo solution

Sponsors & Collaborators

  • Verona Pharma plc

    lead INDUSTRY

Principal Investigators

  • Dr Singh · Medicines Evaluation Unit (MEU)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-01
Primary Completion
2018-01-23
Completion
2018-02-07

Countries

  • Bulgaria
  • Czechia
  • Germany
  • Poland
  • Romania
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03443414 on ClinicalTrials.gov